Fregni F, Nitsche M A, Loo C K, Brunoni A R, Marangolo P, Leite J, Carvalho S, Bolognini N, Caumo W, Paik N J, Simis M, Ueda K, Ekhitari H, Luu P, Tucker D M, Tyler W J, Brunelin J, Datta A, Juan C H, Venkatasubramanian G, Boggio P S, Bikson M
Spaulding Neuromodulation Center, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Department of Clinical Neurophysiology, Georg-August-University, Göttingen, Germany.
Clin Res Regul Aff. 2015 Mar 1;32(1):22-35. doi: 10.3109/10601333.2015.980944.
The field of transcranial electrical stimulation (tES) has experienced significant growth in the past 15 years. One of the tES techniques leading this increased interest is transcranial direct current stimulation (tDCS). Significant research efforts have been devoted to determining the clinical potential of tDCS in humans. Despite the promising results obtained with tDCS in basic and clinical neuroscience, further progress has been impeded by a lack of clarity on international regulatory pathways. We therefore convened a group of research and clinician experts on tDCS to review the research and clinical use of tDCS. In this report, we review the regulatory status of tDCS, and we summarize the results according to research, off-label and compassionate use of tDCS in the following countries: Australia, Brazil, France, Germany, India, Iran, Italy, Portugal, South Korea, Taiwan and United States. Research use, off label treatment and compassionate use of tDCS are employed in most of the countries reviewed in this study. It is critical that a global or local effort is organized to pursue definite evidence to either approve and regulate or restrict the use of tDCS in clinical practice on the basis of adequate randomized controlled treatment trials.
在过去15年里,经颅电刺激(tES)领域取得了显著发展。经颅直流电刺激(tDCS)是引领这一兴趣增长的tES技术之一。大量研究致力于确定tDCS在人类中的临床潜力。尽管tDCS在基础和临床神经科学方面取得了令人鼓舞的成果,但国际监管途径缺乏明确性阻碍了进一步进展。因此,我们召集了一组tDCS研究和临床专家,以审查tDCS的研究和临床应用情况。在本报告中,我们审查了tDCS的监管状况,并根据tDCS在以下国家的研究、超说明书用药和同情用药情况总结结果:澳大利亚、巴西、法国、德国、印度、伊朗、意大利、葡萄牙、韩国、台湾地区和美国。本研究审查的大多数国家都采用了tDCS的研究用途、超说明书治疗和同情用药。至关重要的是,应组织全球或地方层面的努力,以获取确凿证据,从而根据充分的随机对照治疗试验,批准并规范或限制tDCS在临床实践中的使用。